Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to better execute its current strategic plan and enhance market competitiveness [1][2]. Group 1: Restricted Stock Incentive Plan - The company has made revisions to the 2024 Restricted Stock Incentive Plan to effectively motivate the core team to increase the market share of sequencing instruments among non-related customers [1][2]. - The revisions comply with relevant regulations and do not harm the interests of the company and all shareholders [1][2]. Group 2: Employee Stock Ownership Plan - The company has also revised the 2024 Employee Stock Ownership Plan to align with its strategic goals and improve market coverage [2]. - The changes made to the Employee Stock Ownership Plan are consistent with applicable guidelines and do not negatively impact the interests of the company and its shareholders [2].

Core Viewpoint - The legal opinion letter issued by Junhe Law Firm confirms that Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. has obtained the necessary approvals and authorizations for the revision of its 2024 restricted stock incentive plan, which aims to enhance the motivation of incentive targets and align with the company's strategic direction [4][12]. Group 1: Approval and Authorization - The company has completed the necessary procedures for the revision of the incentive plan, including resolutions from the board of directors and supervisory board [4][9]. - The independent directors have publicly solicited proxy voting rights from shareholders regarding the relevant proposals for the incentive plan [5][6]. - The supervisory board has verified the list of incentive targets and issued relevant opinions [6][8]. Group 2: Reasons and Main Content of the Revision - The revision aims to adjust the performance assessment targets at the company level to stimulate the enthusiasm of incentive targets and promote sustainable business development [9][12]. - The main content of the revision includes adjustments to the performance assessment requirements in the incentive plan, with the assessment period set for the 2024-2025 fiscal years [9][11]. - The performance assessment will be based on the company's 2023 revenue of 2.709 billion yuan, excluding revenue related to public health emergencies, with specific growth targets set for each assessment year [10][11]. Group 3: Performance Assessment Targets - The performance assessment targets for the first and second vesting periods are set at 20% and 44% growth, respectively, based on the 2023 revenue [9][10]. - The assessment will also consider the sales growth of gene sequencers, with specific targets established for each year [11][12]. - Adjustments to the performance targets may occur in the event of significant corporate changes affecting revenue [10][12].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to revise its 2024 restricted stock incentive plan and employee stock ownership plan to enhance employee motivation and align with the company's strategic goals in the context of the evolving market environment [10][11]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting restricted stocks to key personnel, including directors, senior management, and core technical staff, to align their interests with the company's long-term performance [1][4]. Necessary Procedures - The company has followed necessary procedures, including board meetings and shareholder approvals, to implement the incentive plan and employee stock ownership plan [5][6][7]. Revision Reasons - The revision is driven by the need to adapt to changes in the external environment and to focus on increasing market share in the gene sequencing equipment sector, which is critical for long-term revenue growth [10][11]. Revised Performance Metrics - The revised performance metrics will include non-related party gene sequencing instrument sales as a key performance indicator, aiming to enhance the company's competitive position and employee engagement [11][12]. Conclusion - The independent financial advisor confirms that the revisions to the incentive plan and employee stock ownership plan have met the necessary review and disclosure obligations and are pending shareholder approval for implementation [14][15].

Core Viewpoint - The company has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to enhance employee motivation and align with its strategic goals, particularly focusing on increasing market share in the gene sequencing industry [1][11]. Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosures for the 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan, which require approval from the shareholders' meeting to be implemented [2][12]. - The supervisory board has verified the related matters of the incentive plan and provided relevant opinions [4][11]. Group 2: Reasons for Revision - The revision aims to adapt to changes in the external environment and the company's actual situation, adding performance assessment indicators related to the sales volume of gene sequencers excluding related parties [6][10]. - The company believes that capturing market share in gene sequencer sales is crucial for driving subsequent reagent sales and revenue growth [6][10]. Group 3: Revised Content - The revised performance assessment indicators now include the sales volume of gene sequencers excluding related parties, with specific targets set for the first and second vesting periods [7][9]. - The performance completion rates and corresponding vesting ratios have been adjusted to reflect the new assessment criteria [8][9]. Group 4: Impact of Revisions - The revisions are expected to effectively motivate employees and support the company's strategic and operational goals without adversely affecting its financial status or operational performance [11][12]. - The adjustments are designed to enhance the company's competitiveness and market coverage, particularly in the context of increasing pressure from macroeconomic factors and competition [10][11].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to implement a restricted stock incentive plan for 2024 to enhance corporate governance, attract and retain talent, and align the interests of shareholders, the company, and employees for long-term development [1][2]. Group 1: Assessment Objectives and Principles - The purpose of the assessment is to improve corporate governance and establish an incentive mechanism to ensure the achievement of the company's strategic and operational goals [2]. - The assessment must adhere to principles of fairness, openness, and justice, linking the incentive plan closely with the performance and contributions of the incentivized individuals [2] Group 2: Assessment Scope and Institutions - The assessment applies to all participants in the incentive plan, including directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [2]. - The Board's Compensation and Assessment Committee leads the assessment, while the Human Resources Center is responsible for implementation and data collection [2][5]. Group 3: Assessment Indicators and Standards - The assessment period for the incentive plan is set for the fiscal years 2024-2025, with annual evaluations based on the company's revenue growth rate and sales growth of sequencing instruments [3][4]. - The performance targets are based on the 2023 revenue of 2.709 billion yuan and the sales of 532 sequencing instruments, with specific growth rates defined for assessment [3][4]. Group 4: Individual Performance Assessment - Individual performance assessments will be conducted according to existing company regulations, with results determining the actual number of shares allocated to each incentivized individual [4]. - The performance rating system categorizes results into five levels (S, A, B, C, D), with corresponding allocation ratios for shares based on performance [4]. Group 5: Assessment Procedures and Results Management - The Human Resources Center is responsible for maintaining assessment results and preparing performance reports for the Compensation and Assessment Committee [5]. - Assessment results are confidential and archived for five years, with provisions for dispute resolution and appeals by assessed individuals [5]. Group 6: Additional Provisions - The plan is subject to approval by the company's shareholders and will be implemented following the effective date of the 2024 incentive plan [6].

Core Viewpoint - The announcement details the completion of the third unlock period for the reserved portion of the 2021 restricted stock incentive plan of Aima Technology, allowing 151,200 shares to be listed and traded starting from August 28, 2025 [1][6][18]. Summary by Sections Incentive Plan Approval and Implementation - The incentive plan was approved by the board and independent directors, with no objections raised during the internal announcement period [2][3]. - The plan includes provisions for the initial grant and adjustments to the list of incentive recipients, which have been verified and approved by the supervisory board [3][4]. Unlock Conditions and Achievements - The third unlock period for the reserved stock began on August 19, 2025, allowing for 40% of the granted shares to be unlocked [9][11]. - The conditions for unlocking have been met, including no adverse audit opinions and compliance with performance targets [10][11]. Performance Assessment - The performance assessment for unlocking shares is based on revenue and net profit growth rates, with specific targets set for the years 2022 to 2024 [11][12]. - The company aims for a net profit growth rate of at least 60% for the year 2024 to meet the unlocking conditions [11]. Listing and Share Structure Changes - The total number of shares to be unlocked is 151,200, which represents approximately 0.0174% of the company's total share capital [14][16]. - Following the unlock, the number of restricted shares will decrease, while the number of unrestricted shares will increase correspondingly [16]. Opinions from Committees and Advisors - The remuneration and assessment committee, supervisory board, and legal advisors have all confirmed that the unlocking conditions have been satisfied and that the process complies with relevant regulations [17][18].

Core Points - The company is holding its third extraordinary general meeting of shareholders in 2025 to discuss the 2025 Restricted Stock Incentive Plan [5][6] - The meeting will take place on August 28, 2025, at 14:00 in Changsha, Hunan Province [4] - The agenda includes the election of vote counters, discussion of proposals, and voting on the incentive plan [5] Meeting Procedures - Shareholders must register 20 minutes before the meeting and present necessary identification [1] - The meeting will follow a structured agenda, including a report on the number of shareholders present and their voting rights [4] - Voting will be conducted via a named ballot system, with each share carrying one vote [2][4] Proposals - Proposal 1: Approval of the 2025 Restricted Stock Incentive Plan draft, aimed at enhancing corporate governance and attracting talent [5][6] - Proposal 2: Approval of the implementation assessment management measures for the 2025 Restricted Stock Incentive Plan [5][6] - Proposal 3: Authorization for the board to manage the implementation of the 2025 Restricted Stock Incentive Plan, including determining eligibility and adjusting stock grants [6][7]

Core Viewpoint - Shenzhen Biyimi Microelectronics Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including the cancellation of the supervisory board and the implementation of a stock incentive plan [1][4]. Group 1: Meeting Proposals - Proposal One: The company plans to cancel the supervisory board and amend the Articles of Association, allowing the audit committee of the board to assume the supervisory functions as per the Company Law [4][5]. - Proposal Two: The company intends to revise certain management systems in accordance with updated regulations and its actual situation, including changes to the rules governing shareholder meetings [6][7]. - Proposal Three: A draft of the 2025 Restricted Stock Incentive Plan is proposed, aiming to attract and retain talent by granting 623,700 shares of restricted stock, which represents 0.89% of the total share capital [8][9]. - Proposal Four: The company has developed an implementation assessment management method for the 2025 Restricted Stock Incentive Plan to ensure its effective execution [10]. - Proposal Five: The board seeks authorization from the shareholders to manage the 2025 Restricted Stock Incentive Plan, including determining eligibility and handling necessary administrative tasks [11]. Group 2: Meeting Procedures - Attendees must sign in 30 minutes before the meeting and present identification or business registration documents [2][3]. - The meeting will follow a structured agenda, including the announcement of attendees and the voting process, which will combine both on-site and online voting [4][5]. - Legal representatives will witness the meeting and provide legal opinions on the proceedings [4][10].

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss and vote on several key proposals related to stock incentive plans and corporate governance [4][5][6]. Group 1: Stock Incentive Plans - The company proposes to authorize the board to implement the 2025 Restricted Stock Incentive Plan, aimed at attracting and retaining talent while aligning the interests of shareholders, the company, and individuals [6][8]. - The plan includes provisions for adjusting the number of restricted stocks and their grant prices in case of capital changes, stock dividends, or other corporate actions [9][10]. - A management method for the implementation of the 2025 Restricted Stock Incentive Plan has been developed to ensure its smooth execution [8][9]. Group 2: Employee Stock Ownership Plan - The company is also proposing an Employee Stock Ownership Plan (ESOP) to enhance employee engagement and align their interests with those of the company [11][12]. - The board seeks authorization to manage the ESOP, including selecting participants and handling stock transactions [13][14]. Group 3: Corporate Governance Changes - The company plans to abolish the supervisory board and allow the audit committee to assume its responsibilities, in accordance with the revised Company Law [14][15]. - Amendments to the company's articles of association will be made to reflect this change and improve corporate governance practices [15][16]. - The company will also propose revisions to various governance systems to align with the new structure and regulatory requirements [17].

Core Viewpoint - The company has adjusted the grant price of the 2024 restricted stock incentive plan following the completion of its mid-term and annual profit distribution plans, ensuring compliance with relevant regulations and maintaining shareholder interests [4][6][7]. Group 1: Decision-Making Process and Disclosure - The company held multiple meetings to review and approve the 2024 restricted stock incentive plan, including the draft and management measures [1][2]. - The independent directors collected proxy votes from shareholders for the plan, and the proposed list of incentive recipients was publicly disclosed without objections [2][3]. Group 2: Adjustment Reasons and Results - The adjustment of the grant price was necessitated by the implementation of cash dividends, which required recalculating the grant price according to the established formula [6]. - The adjusted grant price is approximately 10.67 yuan per share, down from the previous price of 10.88 yuan, after accounting for the cash dividends distributed [6]. Group 3: Impact of Adjustments - The adjustment of the grant price will not materially affect the company's financial status or operational results, and the incentive plan will continue to be implemented as planned [7]. Group 4: Committee and Legal Opinions - The remuneration and assessment committee approved the adjustment, confirming that the process adhered to legal and regulatory requirements [7]. - Legal opinions affirm that the adjustments and related actions comply with the relevant management measures and listing rules [7].